The HPRA advises healthcare professionals not to retain printed versions of Summary of Product Characteristics (SPC) documents. As these documents are subject to frequent content updates, including changes to safety and dose related information, we recommend that you visit our website as necessary to access the most up-to-date versions. If you have any queries about specific SPCs on our website then please e-mail info@hpra.ie


Adrovance 70 mg/2800 IU tablets

70 mg/2800 international unit(s) Tablet

Merck Sharp & Dohme BV,EU/1/06/364/001-004

Main Information

Trade NameAdrovance 70 mg/2800 IU tablets
Active SubstancesAlendronic acid
Vitamin D3
Strength70 mg/2800 international unit(s)
Dosage FormTablet
Licence HolderMerck Sharp & Dohme BV,
Licence NumberEU/1/06/364/001-004

Group Information

ATC CodeM05BB03 alendronic acid and colecalciferol

Status

Authorised/WithdrawnAuthorised
Licence Issued04/01/2007
Legal statusProduct subject to prescription which may be renewed (B)
Supply StatusSupply through pharmacies only
Advertising StatusAdvertising to healthcare professionals only
Conditions of Licence
Marketing Status

Documents

Summary of Product CharacteristicsSearch EMA website
Package LeafletSearch EMA website
Public Assessment ReportSearch EMA website

Generics Information

Interchangeable List CodeIC0052-102-002
Interchangeable List DocumentPDF of Interchangeable List
« Back